- Global Pharma News & Resources

Guerbet Announces Commercial Partnership With Imalogix™ to Deliver Diagnostic and Interventional Imaging Care Optimization

Guerbet Announces Commercial Partnership With Imalogix™ to Deliver Diagnostic and Interventional Imaging Care Optimization

PR Newswire

PRINCETON, N.J., Aug. 13, 2018

PRINCETON, N.J., Aug. 13, 2018 /PRNewswire/ -- Guerbet LLC USA, the U.S. affiliate of the global specialist in contrast product and solutions for medical imaging, announced today a commercial partnership with Imalogix™, a leader in artificial intelligence process and workflow solutions. The Imalogix™ Platform gives healthcare organizations the tools to understand and manage the process, quality and safety related to diagnostic imaging and interventional procedures, and meet evolving regulatory standards surrounding radiation dose management with ease.

The commercial partnership combines Guerbet's leadership in diagnostic and interventional imaging with the cloud-based human and machine-intelligence capabilities of Imalogix™ to proactively identify areas that impact care delivery to reduce variability and improve the quality, safety and efficiency of care around radiation dose management.

"Guerbet is thrilled to deliver an AI-powered solution that brings together data in a meaningful way to evolve the standard of care to patients for managing radiation dose," said Massimo Carrara, Guerbet Vice President for North America. "By partnering with such a recognized expert in the field, Guerbet remains focused on offering the best in diagnostic imaging in a rapidly evolving industry."

The Imalogix™ self-learning neural network enables organizations to understand and benchmark in real-time best practices from the mass learnings across a network of providers to drive continuous improvement. Deep learning recommendations highlight where and how changes can be made to enable organizations to proactively change behavior down to the scanner, protocol and operator level. Insights into procedure length, utilization, and workflow help organizations understand how to become more efficient and optimize patient flow. 

"We are excited to partner with Guerbet who has an extensive track record of innovation. This partnership further demonstrates their commitment to grow and expand their digital offerings to bring best-in-class solutions to their customers," said John Heil, CEO of Imalogix™.

Guerbet is a pioneer in the contrast-agent field, with more than 90 years' experience, and is a leader in medical imaging worldwide. It offers a comprehensive range of pharmaceutical products, medical devices and services for diagnostic and interventional imaging, to improve the diagnosis and treatment of patients. With 8% of revenue dedicated to R&D and more than 200 employees distributed amongst its four centers in France, Israel and the United States, Guerbet is a substantial investor in research and innovation. Guerbet (GBT) is listed on Euronext Paris (segment B – mid caps) and generated €807 million in revenue in 2017. For more information about Guerbet, please visit

Imalogix is a leader in artificial intelligence and workflow solutions that support healthcare providers to better understand and mange process, quality and safety relation to diagnostic imaging services, interventional procedures, and meet evolving regulatory standards with ease. Imalogix has been exclusively endorsed by the American Hospital Association. For more information, visit

View original content with multimedia:


Editor Details

Last Updated: 13-Aug-2018